KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Quality comparison of mediastinal lymph node dissection between video-assisted thoracic surgery and open thoracotomy: a supplementary analysis of the phase 3 Japan Clinical Oncology Group 1413 trial†. PMID 40578313 · Eur J Cardiothorac Surg · 2025-Jul-01 The report is a secondary analysis of a Phase III RCT comparing surgical techniques, not a drug intervention. The primary endpoint is N2 upstaging, a categorical pathological endpoint, not a time-to-event efficacy endpoint (OS, PFS, etc.). Therefore, it does not meet the core criteria for inclusion in this oncology KM digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluating the Efficacy of MamaLift Plus Digital Therapeutic Mobile App for Postpartum Depression (SuMMER): Randomized, Placebo-Controlled Pivotal Trial. PMID 40549508 · J Med Internet Res · 2025-Jul-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of losartan plus modified FOLFIRINOX versus modified FOLFIRINOX in advanced pancreatic cancers: A randomized clinical trial (AFPAC Study). PMID 40542713 · Cancer · 2025-Jul-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 2 Panel · risk visible
INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curse. PMID 40455046 · JNCI Cancer Spectr · 2025-Jul-01 The report is a secondary analysis of pooled phase 2/3 trial data, not the primary result report of the phase III/IIIb or phase II/III trial itself. Furthermore, the specific drug intervention(s) are not identified in the provided record, preventing confirmation of a drug-containing intervention.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological Analysis. PMID 40451185 · JAMA Oncol · 2025-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical Trial. PMID 40434784 · JAMA Surg · 2025-Jul-01 Study is an oncology Phase 3 randomized trial with time-to-event endpoints and original results, but the interventions (CRT-TEM vs TME) do not meet the requirement for a drug-containing intervention as defined by a specific pharmaceutical agent vs another agent or placebo.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE. PMID 40424051 · Diabetes Care · 2025-Jul-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of definitive uterine artery occlusion on ovarian reserve markers in laparoscopic myomectomy: a randomized controlled trial with 2-year follow-up. PMID 40420404 · Hum Reprod · 2025-Jul-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Extent of coronary artery disease and clinical outcomes with ticagrelor monotherapy versus aspirin after coronary artery bypass grafting: insights from the TiCAB trial. PMID 40411761 · Eur J Cardiothorac Surg · 2025-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial. PMID 40404393 · J Nucl Med · 2025-Jul-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
ctDNA and Recurrence Risk for Adjuvant De-Escalation in HPV-Positive Oropharyngeal Carcinoma: A Secondary Analysis of the DART Phase 3 Randomized Clinical Trial. PMID 40402484 · JAMA Otolaryngol Head Neck Surg · 2025-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Dexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients: The A2B Randomized Clinical Trial. PMID 40388916 · JAMA · 2025-Jul-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial. PMID 40372727 · JAMA Oncol · 2025-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia: Results of the Randomized GATLA 8-LMA-P'07 Trial. PMID 40367210 · J Pediatr Hematol Oncol · 2025-Jul-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical Trial. PMID 40354061 · JAMA Neurol · 2025-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial. PMID 40332898 · JAMA Dermatol · 2025-Jul-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical Trial. PMID 40305055 · JAMA Dermatol · 2025-Jul-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study. PMID 40300087 · Clin Cancer Res · 2025-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. PMID 40300079 · Clin Cancer Res · 2025-Jul-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial. PMID 40260648 · Clin Cancer Res · 2025-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program. PMID 40243198 · Cancer Prev Res (Phila) · 2025-Jul-01 While the study meets several criteria (randomized, phase III, human, time-to-event endpoint), it is excluded because it is not a therapeutic trial for an existing malignant neoplasm. It is a cancer prevention trial in a diabetes population, and the intervention is not a drug-containing regimen for treating diagnosed cancer.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes. PMID 40209850 · Cancer Lett · 2025-Jul-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Sex differences in blood pressure lowering of initial treatment with ultra-low dose combination therapy versus monotherapy. A secondary analysis of QUARTET. PMID 40178246 · J Hypertens · 2025-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: a post hoc analysis of the OHZORA trial. PMID 40139716 · Rheumatology (Oxford) · 2025-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A minimal clinically important difference for the sleep inertia visual analog scale in idiopathic hypersomnia. PMID 40135693 · J Clin Sleep Med · 2025-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of adjuvant chemotherapy with toad venom injection in the treatment of intermediate and advanced colon cancer and its effect on cellular immunity, PTEN, and PI3k. PMID 39964699 · Anticancer Drugs · 2025-Jul-01 The record is a randomized oncology trial with a drug intervention and reports original results, but it lacks the required primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.) as a formal, quantitative outcome. The study reports a 1-year survival rate as a simple proportion without Kaplan-Meier analysis or hazard ratio, which does not meet the time-to-event criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term survival from a randomized controlled trial of lobectomy by video-assisted thoracoscopic surgery versus thoracotomy for early-stage lung cancer. PMID 39873729 · Eur J Cardiothorac Surg · 2025-Jul-01 The study is a randomized, oncology trial with time-to-event endpoints and is an original result report. However, it compares two surgical techniques (VATS vs. thoracotomy) and does not involve a drug-containing intervention, which is a required criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Three-year Survival Outcomes of Patients With Enhanced Recovery After Surgery Versus Conventional Care in Laparoscopic Distal Gastrectomy: The GISSG1901 Randomized Clinical Trial. PMID 39660451 · Ann Surg · 2025-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Identification and Categorization of Technical Errors and Hazard Zones of Robotic Versus Laparoscopic Total Gastrectomy for Gastric Cancer: A Single-center Prospective Randomized Controlled Study. PMID 39513271 · Ann Surg · 2025-Jul-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Paravertebral Versus EPidural Analgesia in Minimally Invasive Esophageal ResectioN (PEPMEN): A Randomized Controlled Multicenter Trial. PMID 39360422 · Ann Surg · 2025-Jul-01 The study is a randomized trial in esophageal cancer (oncology, human), but the intervention is purely procedural (analgesia techniques), not a drug-containing intervention. The primary outcome is quality of recovery (QoR-40), a patient-reported outcome measure, not a time-to-event efficacy endpoint. Secondary outcomes include quality of life and complications, but no time-to-event efficacy endpoints like OS, PFS, DFS, EFS, RFS, TTP, or time-to-event analyses (Kaplan-Meier, HR) are reported. Therefore, it does not meet the required criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases: Final Results From the Phase III Randomized Controlled Trial SCANDIUM. PMID 38420778 · Ann Surg · 2025-Jul-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 6 Panel · risk unclear
Emerging Role of Multiparametric MRI in the Staging of Bladder Cancer: Insights From the BladderPath Trial. PMID 40861675 · Cureus · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effects of an Afrocentric Sexual Health Education Curriculum for Medical, Nursing, and Midwifery Students in Tanzania: A Single-Blinded Randomized Controlled Phase 3 Trial. PMID 40789797 · Arch Sex Behav · 2025-Jul 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effects of the "Internet +" nursing model based on user profiling on postoperative recovery in breast cancer: A prospective randomized controlled clinical trial. PMID 40786863 · Int J Nurs Sci · 2025-Jul The study is a randomized, prospective, human oncology trial with primary results. However, it is excluded because it does not meet the core eligibility criteria: it is not reported as a Phase III/IIIb or Phase II/III trial, the intervention is a non-drug 'Internet+' nursing model, and the primary endpoints are quality-of-life and symptom scores (FOP-Q-SF, FCRI-SF, C-PTGI, FACT-B), not a time-to-event efficacy endpoint like OS, PFS, or DFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Methylphenidate versus placebo for fatigue in patients with advanced cancer: the MePFAC randomised controlled trial. PMID 40755226 · Health Technol Assess · 2025-Jul The trial is an oncology, human, randomized, Phase III drug intervention with original results, but it fails the time-to-event endpoint criterion. The primary outcome is a patient-reported fatigue score (FACT-Fatigue), not OS, PFS, DFS, EFS, RFS, TTP, or any other time-to-event measure. Survival is mentioned only as a secondary outcome with no time-to-event analysis details.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of human fibrinogen concentrate (BT524) in patients with major haemorrhage undergoing major orthopaedic or abdominal surgery (AdFIrst): a randomised, active-controlled, multicentre, partially blinded, phase 3 non-inferiority trial. PMID 40741224 · EClinicalMedicine · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Outcomes of posterior lamellar tarsal rotation vs bilamellar tarsal rotation for trachomatous trichiasis. PMID 40737343 · PLoS Negl Trop Dis · 2025-Jul 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: A Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. PMID 40736776 · Allergy Asthma Immunol Res · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Shufeng Jiedu Granule against mild COVID-19: Protocol of the randomized, double-blind, placebo-controlled, multi-center heal-COVID phase III study. PMID 40734912 · Chin Herb Med · 2025-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dupilumab Plus Medium-Dose Inhaled Corticosteroid (ICS) Improves Outcomes Compared With Placebo Plus Continued High-Dose ICS in Children With Uncontrolled Moderate-to-Severe Type 2 Asthma. PMID 40728026 · Pediatr Pulmonol · 2025-Jul 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Brexpiprazole's impacts on patients and caregivers in agitation in Alzheimer's dementia. PMID 40717666 · Alzheimers Dement · 2025-Jul 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Empirical Derivation and Prediction of Treatment Trajectories in Harmonized AUD Clinical Trial Datasets. PMID 40700031 · Addict Biol · 2025-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
An overview of randomized phase III clinical trials of cancer nanomedicines. PMID 40697515 · Cancer Pathog Ther · 2025-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial. PMID 40697509 · Cancer Pathog Ther · 2025-Jul 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 3 Panel · risk visible
Trastuzumab in early curative breast cancer: A target trial emulation benchmarked against two randomized clinical trials. PMID 40690519 · PLoS Med · 2025-Jul The record describes an observational analysis (target trial emulation) benchmarked against two existing randomized trials (B-31 and N9831). It is not an original formal-result report of a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a time-to-event efficacy endpoint. While it discusses and cites Phase III trials, the report itself does not present the results of such a trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Group-based interventions to reduce gambling involvement among male football fans: a synopsis of findings from a feasibility study. PMID 40690427 · Public Health Res (Southampt) · 2025-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial. PMID 40686671 · EClinicalMedicine · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Doravirine-based Regimens by Sex and Race: Long-term Results From Three Phase 3 Clinical Trials. PMID 40672760 · Open Forum Infect Dis · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Donanemab exposure-response in early symptomatic Alzheimer's disease. PMID 40667684 · Alzheimers Dement · 2025-Jul 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: A Randomized Clinical Trial. PMID 40663622 · Circ Cardiovasc Interv · 2025-Jul 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -